Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1127749

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: BioMarin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the progress of talks on procuring medicines between the NHS and Bio Marin.
tabling member constituency	Gloucester
tabling member printed	Richard Graham
uin	256971
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>We have made no such assessment. Discussions about commercial agreements for medicines are rightly held between NHS England as an independent body and the manufacturer concerned. The Department plays no role in such discussions.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:48:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	3990 label Biography information for Richard Graham

1127772

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the review of the methods for the NICE Technology Appraisal Programme referred to in the 2019 voluntary scheme for branded medicines pricing and access will include support for earlier patient access to innovative medicines.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	257056
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve patient organisations and other relevant stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing and Access sets out the Department’s expectation that that any future changes to NICE methods and processes would support faster adoption of the most clinically and cost effective medicines. Additional detail and more information will be made available on the NICE website in due course.</p><p>The 2019 Voluntary Scheme also states that NICE will adopt the principle of appraisal timelines for non-oncology treatments matching the faster timescales for oncology treatments, subject to the evidence base for the product being sufficiently developed to enable a NICE appraisal with the same level of rigour and certainty as would be expected currently.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:52:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	4398 label Biography information for Chris Green

1127892

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what (a) health-and-safety research and (b) risk assessments his Department has (i) undertaken and (ii) commissioned on 5G technology.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256910
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>This explains the health-related reviews and assessments have been performed, as well as the practical measures that are in place to protect public health.</p><p>PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The guidelines apply to exposures at frequencies up to 300 GHz, well above the maximum few tens of GHz frequencies anticipated for use by 5G systems.</p><p>Health and safety legislation requires companies deploying and operating communication networks to carry out suitable and sufficient risk assessments, as well as put in place measures to reduce the identified risks so far as reasonably practicable. In controlling risks arising from radio wave exposure, the Health and Safety Executive refer to compliance with the ICNIRP guidelines. Industry has committed to comply with the international guidelines and to provide certificates of compliance with planning applications for base stations.</p><p>PHE continues to monitor the health-related evidence applicable to radio waves, including in relation to base stations, and is committed to updating its advice as required.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256911 256912 question first answered 29/05/2019 10:34:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127893

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of including in the mandatory part of every diabetes appointment a question on the mental wellbeing of a patient.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	257108
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>NHS England has informed us that is has not assessed the case for mandatory inclusion of this question in every diabetes appointment. The NHS Long Term Plan committed to increasing the provision of mental health support for all patients who require it and NHS England is currently taking forward a number of initiatives to deliver this for patients including for those living with diabetes.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:57:05 answering member 4455 label Biography information for Seema Kennedy
tabling member	4511 label Biography information for Dr Rupa Huq

1127894

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has (a) undertaken and (b) commissioned a regulatory safety testing on 5G radiofrequency radiation.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256911
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>This explains the health-related reviews and assessments have been performed, as well as the practical measures that are in place to protect public health.</p><p>PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The guidelines apply to exposures at frequencies up to 300 GHz, well above the maximum few tens of GHz frequencies anticipated for use by 5G systems.</p><p>Health and safety legislation requires companies deploying and operating communication networks to carry out suitable and sufficient risk assessments, as well as put in place measures to reduce the identified risks so far as reasonably practicable. In controlling risks arising from radio wave exposure, the Health and Safety Executive refer to compliance with the ICNIRP guidelines. Industry has committed to comply with the international guidelines and to provide certificates of compliance with planning applications for base stations.</p><p>PHE continues to monitor the health-related evidence applicable to radio waves, including in relation to base stations, and is committed to updating its advice as required.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256910 256912 question first answered 29/05/2019 10:34:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127896

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to undertake (a) health-and-safety research and (b) a risk assessments before 5G is adopted in a localised test area.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256912
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>This explains the health-related reviews and assessments have been performed, as well as the practical measures that are in place to protect public health.</p><p>PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The guidelines apply to exposures at frequencies up to 300 GHz, well above the maximum few tens of GHz frequencies anticipated for use by 5G systems.</p><p>Health and safety legislation requires companies deploying and operating communication networks to carry out suitable and sufficient risk assessments, as well as put in place measures to reduce the identified risks so far as reasonably practicable. In controlling risks arising from radio wave exposure, the Health and Safety Executive refer to compliance with the ICNIRP guidelines. Industry has committed to comply with the international guidelines and to provide certificates of compliance with planning applications for base stations.</p><p>PHE continues to monitor the health-related evidence applicable to radio waves, including in relation to base stations, and is committed to updating its advice as required.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256910 256911 question first answered 29/05/2019 10:34:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127908

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether an assessment has been made of the potential benefits of including a mental health professional with knowledge of diabetes in every diabetes care team.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	257109
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>It is for individual clinical commissioning groups to commission treatment and services for people with diabetes and they are best placed to identify what is needed in their local areas.</p><p>On 21 March 2018, NHS England and NHS Improvement along with the National Collaborating Cenre for Mental Health published ‘The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms’.</p><p>IAPT services provide evidence based treatments for people with anxiety and depression and the services are co-located in existing primary and secondary care physical health pathways. IAPT services will target the needs of people with depression and anxiety disorders who also have long-term conditions such as diabetes.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 29/05/2019 13:39:35 answering member 4455 label Biography information for Seema Kennedy
tabling member	4511 label Biography information for Dr Rupa Huq

1127949

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what studies have been carried out to evaluate the effect of 5G on (a) pregnant women, (b) babies and (c) young children.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256920
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>A considerable amount of research has been carried out on exposure to radio waves over several decades, and evidence reviews have been prepared by scientific expert groups in the United Kingdom and around the world. Among the health topics investigated is whether adverse effects can occur in relation to reproduction and development.</p><p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>Based on the accumulated evidence and reviews, PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. This includes effects in relation to reproduction and development.</p><p>PHE has committed to keeping the emerging evidence under review and to preparing another comprehensive review when sufficient new evidence has accumulated.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:39:58 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127499

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has held with (a) NICE, (b) NHS England and (c) Biogen on a Managed Access Agreement for SMA treatment Spinraza.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256254
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256255 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1127500

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256255
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256254 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper